UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer

UCB's expertise in macrocyclic peptide discovery, using its proprietary mRNA-display platform, ExtremeDiversity, will aid Ariceum's discovery of treatments for solid tumorsAriceum's expertise

Related Keywords

United States ,Brussels ,Bruxelles Capitale ,Belgium ,Berlin ,Germany ,Australia ,Switzerland ,America ,Marie Curie ,Dhaval Patel ,Pureos Bioventures ,Life Sciences ,Chief Executive Officer ,Ariceum Therapeutics ,Chief Scientific Officer ,North America ,Andera Partners ,Earlybird Venture ,Euronext Brussels ,Gefallene Big Techs ,Ariceum ,Herapeutics ,Sign ,Strategic ,Research ,Collaboration ,Discover ,Modalities ,Treatment ,Immune ,Elated ,Diseases ,Dancer ,